Microwave-triggered/HSP-targeted gold nano-system for triple-negative breast cancer photothermal therapy

被引:33
|
作者
Cheng, Ying [1 ]
Bao, Dandan [2 ]
Chen, Xiaojie [1 ]
Wu, Yajun [3 ]
Wei, Yinghui [1 ]
Wu, Zhibing [4 ]
Li, Fanzhu [1 ]
Piao, Ji-Gang [1 ]
机构
[1] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Peoples R China
[2] Zhejiang Chinese Med Univ, Dept Dermatol & Cosmetol, Affiliated Hosp 1, Hangzhou 310006, Peoples R China
[3] Zhejiang Hosp, Pharm Dept, Hangzhou 310013, Peoples R China
[4] Zhejiang Hosp, Dept Oncol, Hangzhou 310013, Peoples R China
基金
中国国家自然科学基金;
关键词
Gold nanocage; Photothermal therapy; Triple-negative breast cancer; Heat shock protein; Targeted nano-system; HEAT-SHOCK PROTEINS; ENHANCED PERMEABILITY; NANOCAGES; RETENTION; NANOPARTICLES; NANOMATERIALS; NANOMEDICINE; CHALLENGES;
D O I
10.1016/j.ijpharm.2020.120162
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to the lack of effective therapeutic targets and the passive delivery of a limited quantity of nanoparticles to the tumors, the photothermal conversion agents used in photothermal therapy (PTT) have not been effective in treating triple-negative breast cancer (TNBC). As a result, there is a need to improve the tumor-targeting ability of these photothermal conversion agents. To address this, a microwave-triggered heat shock protein (HSP)-targeted gold nano-system (cmHSP-AuNC), with a gold nanocage (AuNC) as a photothermal conversion agent and anti-HSP monoclonal antibody (cmHSP) as a targeting ligand, was fabricated. cmHSP-AuNC was characterized based on morphology, particle size, zeta potentials, absorption spectrum, and photothermal conversion ability. The expression of HSP70 in 4T1 cells after microwave irradiation was verified by western blotting, and the optimal treatment conditions to achieve the highest expression were determined. Both in vitro and in vivo results indicated that the induction through microwave irradiation could effectively activate the HSP70 overexpression in TNBC, thereby significantly improving the targeting ability, tumor accumulation and anti-tumor efficacy of cmHSP-AuNC. This study proposes a promising strategy for improving the targeting ability and therapeutic efficacy of PTT.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer
    Shahbazi, Reza
    Asik, Elif
    Kahraman, Nermin
    Turk, Mustafa
    Ozpolat, Bulent
    Ulubayram, Kezban
    NANOMEDICINE, 2017, 12 (16) : 1961 - 1973
  • [12] Targeted Therapies in Triple-Negative Breast Cancer
    Marme, Frederik
    Schneeweiss, Andreas
    BREAST CARE, 2015, 10 (03) : 159 - 166
  • [13] Targeted Treatment of Triple-Negative Breast Cancer
    Young, Joanna A.
    Tan, Antoinette R.
    CANCER JOURNAL, 2021, 27 (01): : 50 - 58
  • [14] Targeted Therapies for Triple-Negative Breast Cancer
    Tomas G. Lyons
    Current Treatment Options in Oncology, 2019, 20
  • [15] Targeted Therapies for Triple-Negative Breast Cancer
    Lyons, Tomas G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (11)
  • [16] Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy
    Vidula, Neelima
    Rugo, Hope S.
    CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1511 - 1513
  • [17] Current advances in biomarkers for targeted therapy in triple-negative breast cancer
    Fleisher, Brett
    Clarke, Charlotte
    Ait-Oudhia, Sihem
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 183 - 197
  • [18] Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
    Raju, V.
    Yasothamani, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S1272 - S1272
  • [19] Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer
    Nedeljkovic, Milica
    Vuletic, Ana
    Martinovic, Katarina Mirjacic
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)
  • [20] Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer
    Kumari, Mamta
    Krishnamurthy, Praveen Thaggikuppe
    Sola, Piyong
    CURRENT CANCER DRUG TARGETS, 2020, 20 (08) : 559 - 572